• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, October 1, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Epilepsy Drugs Successfully Reverse Autism Symptoms in Mice, New Study Finds

Bioengineer by Bioengineer
September 6, 2025
in Health
Reading Time: 3 mins read
0
Epilepsy Drugs Successfully Reverse Autism Symptoms in Mice, New Study Finds
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The RTN, situated at the interface between the thalamus and cerebral cortex, functions primarily as a gatekeeper of sensory information, regulating the flow of incoming stimuli to higher brain regions. Despite previous knowledge linking thalamocortical dysfunction to autism, the precise contributions of RTN hyperexcitability remained elusive until now. Utilizing a well-established Cntnap2 knockout mouse model, which genetically replicates key features of ASD, the research team meticulously recorded neural activity and observed corresponding behaviors.

These genetically modified mice exhibited pronounced increases in RTN neuronal firing rates upon exposure to sensory triggers such as light flashes and air puffs. Even more compelling, the RTN displayed spontaneous bursts of hyperactivity that precipitated seizure events—offering a tangible neural substrate for the elevated co-occurrence of epilepsy in individuals with autism. Indeed, epidemiological data indicate epilepsy affects approximately 30% of people with ASD, starkly contrasting with a 1% prevalence in the general population.

.adsslot_SYbDTwIHGZ{width:728px !important;height:90px !important;}
@media(max-width:1199px){ .adsslot_SYbDTwIHGZ{width:468px !important;height:60px !important;}
}
@media(max-width:767px){ .adsslot_SYbDTwIHGZ{width:320px !important;height:50px !important;}
}

ADVERTISEMENT

Capitalizing on these insights, the researchers administered an experimental antiepileptic drug called Z944, which selectively dampens T-type calcium channel activity implicated in RTN neuron excitability. Remarkably, treatment with Z944 normalized the neural hyperactivity within the RTN and substantially ameliorated autism-like phenotypes in the mouse model. These improvements encompassed reduced sensitivity to external sensory stimuli, diminished seizure susceptibility, decreased repetitive motor behaviors, and enhanced social interaction metrics.

To probe causality more rigorously, the team employed designer receptors exclusively activated by designer drugs (DREADD)-based neuromodulation techniques to either suppress or enhance RTN activity. Suppression of RTN hyperexcitability in autism-model mice recapitulated the beneficial effects seen with pharmacotherapy, while artificially increasing RTN activity in neurotypical mice induced autism-like behavioral deficits. This bidirectional control firmly establishes RTN hyperexcitability as a pivotal mechanistic driver of the observed symptomatology.

This elegant convergence of pharmacogenetics, electrophysiology, and behavioral neuroscience positions the RTN as a novel and promising therapeutic target. Unlike generalized approaches that lack circuit specificity, interventions tuned to normalize RTN function could potentially rectify the sensory processing abnormalities and social deficits hallmarking autism. Moreover, given that Z944 and related compounds are already under exploration for epilepsy treatment, translational hurdles may be minimized, accelerating clinical applications.

The study also illuminates the neurobiological overlap between ASD and epilepsy, suggesting that hyperexcitability within RTN circuits constitutes a shared pathological nexus. This insight may help explain the frequent comorbidity observed between these disorders and invite integrated therapeutic strategies addressing both symptom domains simultaneously.

These findings mark a substantial advancement in the neuroscience of autism, emphasizing the importance of subcortical structures like the RTN in shaping complex behavioral phenotypes. Historically, much ASD research has focused on cortical and synaptic abnormalities; however, this work highlights how dysfunction in sensory gating mechanisms contributes critically to the disorder’s clinical presentation.

Further research is warranted to elucidate the molecular underpinnings driving RTN hyperexcitability in autism models and to determine whether similar patterns manifest in human patients. Longitudinal studies examining the developmental trajectory of RTN activity may also reveal key windows for intervention. Additionally, expanding this neuromodulatory approach to other animal models will be critical to validate the generalizability of the findings.

In sum, the identification of RTN hyperexcitability as a causal factor in autism spectrum behaviors offers a beacon of hope for novel, circuit-targeted treatments. By bridging the gap between basic neuroscience and clinical therapeutics, this research elevates our prospects for mitigating the multifaceted challenges posed by autism.

Subject of Research: Neurological mechanisms underlying autism spectrum disorder, focusing on the reticular thalamic nucleus and its role in sensory processing and behavior modulation.

Article Title: Reticular Thalamic Hyperexcitability Drives Autism Spectrum Disorder Behaviors in the Cntnap2 Model of Autism

News Publication Date: 20-Aug-2025

Web References:
https://www.science.org/doi/10.1126/sciadv.adw4682

References:
Huguenard, J., Jang, S.-S., et al. (2025). Reticular Thalamic Hyperexcitability Drives Autism Spectrum Disorder Behaviors in the Cntnap2 Model of Autism. Science Advances, DOI:10.1126/sciadv.adw4682.

Keywords: Autism, Epilepsy, Reticular Thalamic Nucleus, Cntnap2, Neuromodulation, Sensory Gating, Seizures, T-type Calcium Channels, DREADD, Behavioral Neuroscience

Tags: autism symptoms reversal with epilepsy drugsbrain circuitry and autism behaviorsCntnap2 knockout mouse model studyepilepsy and autism connectionepilepsy prevalence in autism spectrum disorderneurological circuits in autism researchreticular thalamic nucleus role in autismRTN hyperactivity and seizure correlationsensory information processing in autismStanford Medicine autism researchtargeted treatments for autism spectrum disorderthalamocortical dysfunction in autism

Tags: Autism epilepsy comorbidityCntnap2 mouse modelEpilepsy drug autism reversalReticular thalamic nucleus hyperactivityT-type calcium channels ASD
Share16Tweet10Share3ShareShareShare2

Related Posts

Multilocus Gene Deletion and Conversion at Y-STR

October 1, 2025

Carrying the Weight: Adult Children of Schizophrenic Parents

October 1, 2025

First-Trimester Lipid Levels and Gestational Diabetes Risk

October 1, 2025

Fennel Extract Influences Hormones in Infertile Women

October 1, 2025

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    89 shares
    Share 36 Tweet 22
  • Physicists Develop Visible Time Crystal for the First Time

    74 shares
    Share 30 Tweet 19
  • How Donor Human Milk Storage Impacts Gut Health in Preemies

    62 shares
    Share 25 Tweet 16
  • Scientists Discover and Synthesize Active Compound in Magic Mushrooms Again

    57 shares
    Share 23 Tweet 14

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Can We Differentiate Distal Femur Variations from Lesions?

Multilocus Gene Deletion and Conversion at Y-STR

Revealing White Cell Markers in Sepsis, NEC Diagnosis

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 59 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.